Literature DB >> 12451471

Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.

Shogo Ozawa1, Masashi Hamada, Norie Murayama, Yukiko Nakajima, Nahoko Kaniwa, Yoshiaki Matsumoto, Masamichi Fukuoka, Jun-ichi Sawada, Yasuo Ohno.   

Abstract

PURPOSE: The enzymatic formation of 5-fluorouracil (5-FU) from two fluoropyrimidine prodrugs, doxifluridine (5'-DFUR) and tegafur (FT), was compared in vitro in order to determine whether there are differences between the metabolic profiles of the two prodrugs.
METHODS: Conversion of the two fluoropyrimidine prodrugs to 5-FU was measured by high-performance liquid chromatography at a concentration of 500 micro M using the microsomal and cytosolic fractions of 12 human livers. The degree of correlation between the 5-FU-forming activities was determined using various cytochrome P450-dependent reactions.
RESULTS: Liver microsomes catalyzed 5-FU formation from 5'-DFUR at rates of 10.0-160.1 pmol/min per mg protein and correlated well with CYP2A6-dependent coumarin 7-hydroxylase activity. The rates of microsomal 5-FU formation from FT ranged from 44.9 to 808.3 pmol/min per mg protein and also correlated with coumarin 7-hydroxylase activity. The cytosol fractions catalyzed 5-FU formation from 5'-DFUR at rates of 3,164.6 to 6,026.6 pmol/min per mg protein, almost two orders of magnitude higher than the rates of cytosolic 5-FU formation from FT (46.8-219.0 pmol/min per mg protein).
CONCLUSIONS: The cytosolic enzymes in livers appear to be important for 5-FU formation from 5'-DFUR. Both cytosolic and microsomal enzymes were involved almost equally in 5-FU formation from FT. The increased formation of 5-FU from 5'-DFUR might provide an answer to the question of why similar blood 5-FU levels were retained despite blood 5'-DFUR levels lower than blood FT levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451471     DOI: 10.1007/s00280-002-0528-1

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  3 in total

1.  5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.

Authors:  Jin-Fang Zheng; Hai-Dong Wang
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

2.  Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

Authors:  Marie-Christine Etienne-Grimaldi; Jaafar Bennouna; Jean-Louis Formento; Jean-Yves Douillard; Mireille Francoual; Isabelle Hennebelle; Etienne Chatelut; Eric Francois; Roger Faroux; Chaza El Hannani; Jacques-Henri Jacob; Gérard Milano
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

3.  N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.

Authors:  Xiaofan Zhang; Julia Li Zhong; Wei Liu; Zuhua Gao; Xia Xue; Pan Yue; Limei Wang; Cuirong Zhao; Wenfang Xu; Xianjun Qu
Journal:  Cancer Chemother Pharmacol       Date:  2009-09-16       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.